SMSarah E. McDowell

Sarah E. McDowell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah E. McDowell has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Developing consensus on hospital prescribing indicators of potential harms amenable to decision support

    by Sarah K. Thomas, Sarah E. McDowell, James Hodson, Ugochi Nwulu, Rachel L. Howard, Anthony J. Avery, Ann Slee, Jamie J. Coleman

    Aims: To develop a list of prescribing indicators specific for the hospital setting that would facilitate the prospective collection of high‐severity and/or high‐frequency prescribing errors, which are also amenable to electronic clinical decision support.Methods: A two‐stage consensus technique (electronic Delphi) was carried out with 20 experts across England. Participants were asked to score prescribing errors using a five‐point Likert scale for their likelihood of occurrence and the severity of the most likely outcome. These were combined to produce risk scores, from which median scores were calculated for each indicator across the participants in the study. The degree of consensus between the participants was defined as the proportion that gave a risk score in the same category as the median. Indicators were included if a consensus of 80% or more was achieved.Results: A total of 80 prescribing errors were identified by consensus as being high or extreme risk. The most common drug classes named within the indicators were antibiotics (n = 13), antidepressants (n = 8), nonsteroidal anti‐inflammatory drugs (n = 6) and opioid analgesics (n = 6). The most frequent error type identified as high or extreme risk were those classified as clinical contraindications (n = 29 of 80).Conclusions: Eighty high‐risk prescribing errors in the hospital setting have been identified by an expert panel. These indicators can serve as a standardized, validated tool for the collection of prescribing data in both paper‐based and electronic prescribing processes. This can assess the impact of safety improvement initiatives, such as the implementation of electronic clinical decision support.


  • A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy

    by Sarah E Mcdowell, Sarah K Thomas, Jamie J Coleman, Jeffrey K Aronson, Robin E Ferner

    Summary: Monitoring of patients taking antihypertensive treatment can identify potential adverse drug reactions (ADRs). However, published guidelines give divergent or incomplete recommendations on monitoring for ADRs. Using a predetermined strategy, we undertook a systematic review to identify hypertension guidelines published from January 2001 to October 2011 with recommendations for monitoring for ADRs. We screened 88 abstracts and 187 web-based guidelines, and identified 19 published guidelines on monitoring the biochemical effects of antihypertensive drug therapy. We then produced a set of practical clinical guidelines, synthesized from those recommendations. Our recommendations are designed to provide efficient monitoring. They reduce the number of tests to a minimum consistent with safe practice and align monitoring schedules, so that creatinine, potassium and sodium concentrations are measured at the same times in all cases. The instructions for biochemical monitoring in current guidelines differ greatly, both in the extent of advice and in the detail provided. The current lack of consistent and workable instructions poses serious difficulties for practitioners. The recommendations distilled from this systematic review should help practitioners when they monitor therapy with antihypertensive drugs.


  • Dose Omissions in Hospitalized Patients in a UK Hospital

    by Jamie J. Coleman, Sarah E. McDowell, Robin E. Ferner


  • Improvement in the detection of adverse drug events by the use of electronic health and prescription records: An evaluation of two trigger tools

    by Ugochi Nwulu, Krishnarajah Nirantharakumar, Rachel Odesanya, Sarah E. McDowell, Jamie J. Coleman

    Purpose To test if two of the adverse event triggers proposed by the Institute of Healthcare Improvement can detect adverse drug events (ADEs) in a UK secondary care setting, using an electronic prescribing and health record system. Methods In order to identify triggers for over-anticoagulation and potential opioid overdose and we undertook a retrospective review of electronic medical and prescription records from 54,244 hospital admissions over a 1-year period, alongside a review of medical incident reports. Once prescription data were linked to triggers and duplicates were removed, case note review eliminated the false positive ADEs. Additionally, we tested the use of an electronic algorithm for the International Normalized Ratio (INR) ≥6 trigger. Results The INR ≥6 electronic trigger identified 46 potential ADEs and the naloxone electronic trigger identified 82 ADEs. Based on the available case note review, the INR ≥6 trigger had a positive predictive value (PPV) of 38 % (14/37) and the naloxone trigger had a PPV of 91 % (61/67). The electronic algorithm for the INR ≥6 trigger identified 12 ADEs, thus reducing the need of case note review. This was in comparison with one and two critical incidents reported in the trust medical incident reports system, which respectively related to over-coagulation with warfarin and over-sedation with opioid medication. Conclusions We have integrated automated and manual methods of detecting ADEs using previously defined triggers. Incorporating electronic triggers in already established electronic health records with prescription and laboratory test data can improve the detection of ADEs, and potentially lead to methods to avert them.


  • An agenda for UK clinical pharmacology: The potential of the internet

    by Jamie J. Coleman, Sarah E. McDowell

    The internet and the World Wide Web have changed the ways that we function. As technologies grow and adapt, there is a huge potential for the internet to affect drug research and development, as well as many other aspects of clinical pharmacology. We review some of the areas of interest to date and discuss some of the potential areas in which internet-based technology can be exploited. Information retrieval from the web by health-care professionals is common, and bringing evidence-based medicine to the bedside affects the care of patients. As a primary research tool the web can provide a vast array of information in generating new ideas or exploring previous research findings. This has facilitated systematic reviewing, for example. The content of the web has become a subject of research in its own right. The web is also widely used as a research facilitator, including enhancement of communication between collaborators, provision of online research tools (such as questionnaires, management of large scale multicentre trials, registration of clinical trials) and distribution of information. Problems include information overload, ignorance of early data that are not indexed in databases, difficulties in keeping web sites up to date and assessing the validity of information retrieved. Some web-based activities are viewed with suspicion, including analysis by pharmaceutical companies of drug information to facilitate direct-to-consumer advertising of novel pharmaceuticals. Use of these technologies will continue to expand in often unexpected ways. Clinical pharmacologists must embrace internet technology and include it as a key priority in their research agenda.


  • Biochemical Monitoring of Patients Treated with Antihypertensive Therapy for Adverse Drug Reactions

    by Sarah E. McDowell, Robin E. Ferner

    Biochemical monitoring of patients treated with antihypertensive therapy is recommended in order to identify potential adverse reactions to treatment. We aimed to review the literature investigating...


  • Republished paper: Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis

    by Sarah E McDowell, Shahrul Mt-Isa, Deborah Ashby, R E Ferner

    Objective To investigate the overall probability of error in preparing and administering intravenous medicines; to identify at which stage of the process an error is most likely to occur; and to determine the impact of error correction on the error probability. Design Systematic review and random-effects Bayesian conditional independence modelling. Methods Medline and EMBASE were searched for studies on intravenous medicines. The error rates of each stage were extracted. These, expert estimates, and error rates from generic tasks, were used in a Bayesian conditional independence model to find error ‘hot-spots.’ The main outcome measure was the probability of at least one error occurring during intravenous therapy. Results Nine published studies were identified for inclusion in the systematic review and meta-analysis. The overall probability of making at least one error in intravenous therapy was 0.73 (95% credible interval (CrI) 0.54 to 0.90). If error-checking was introduced at each stage of the process, the overall rate fell to 0.22 (95% CrI 0.14 to 0.31). Errors were most likely in the reconstitution step. Removing the reconstitution step by providing preprepared injections would reduce the overall error rate to 0.17 (95% CrI 0.09 to 0.27). Conclusions Intravenous therapy is complex and error-prone. Error-checking at each stage could reduce the error probability. The use of preprepared injections may help by eliminating errors in the reconstitution of drug and diluent. However, it will be important to ensure that benefits are not outweighed by practical disadvantages such as an increase in selection errors.


  • Open Access

    Oversight: a retrospective study of biochemical monitoring in patients beginning antihypertensive drug treatment in primary care

    by Jamie J. Coleman, Sarah E. McDowell, Stephen J. W. Evans, Paramjit S. Gill, Robin E. Ferner

    WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Guidelines recommend biochemical monitoring of patients treated with antihypertensive agents, although there is little primary evidence for these recommendations. WHAT THIS STUDY ADDS • Patients treated for hypertension in general practice often have no biochemical tests before, or in the 6 months after, starting drug treatment.AIMS: Guidelines on the management of hypertension have recommended baseline testing of serum electrolyte and creatinine concentrations before treatment since the 1990s. We wished to examine the extent of laboratory monitoring in patients with newly diagnosed hypertension and newly treated with antihypertensive drugs.METHODS: We carried out a retrospective analysis of 74 096 patients in the General Practice Research Database (GPRD) aged 18 years and older with newly diagnosed hypertension and prescribed a single antihypertensive agent. We determined the number of patients with a laboratory test for serum electrolyte and creatinine (or urea) concentrations prior to the first antihypertensive drug prescription and in the 6 months after and patient factors associated with subsequent monitoring.RESULTS: Thirty‐four thousand nine hundred and forty‐seven patients (47%) had at least one biochemical test in the 12 months prior to beginning antihypertensive treatment, and 26 946 (36%) had at least one biochemical monitoring test in the 6 months after beginning antihypertensive treatment. Thirteen thousand five hundred and four (18%) had both baseline and monitoring tests. Baseline tests were normal in 11 671 patients (86%), of whom 10 213 (88%) had normal tests at first monitoring. Monitoring was significantly more likely in patients treated with ACE inhibitors than thiazides (adjusted OR 1.90; 95% CI 1.80, 2.00), older patients (adjusted OR 1.23; 95% CI 1.11, 1.36) [individuals aged 80–89 years compared with <40 years], and patients with diabetes mellitus (adjusted OR 2.03; 95% CI 1.91, 2.16).CONCLUSION: Biochemical testing at baseline and monitoring after starting treatment is often omitted in newly diagnosed hypertensive patients. When both are tested, one in eight normal results becomes abnormal.


  • Correlates of spontaneous reporting of adverse drug reactions within primary care: the paradox of low prescribers who are high reporters

    by Anthony R. Cox, Christopher Anton, Sarah E. McDowell, John F. Marriott, Robin E. Ferner

    To examine Primary Care Trust (PCT) demographics influencing general practitioner (GP) involvement in pharmacovigilance. PCT adverse drug reaction (ADR) reports to the Yellow Card scheme between April 2004 and March 2006 were obtained for the UK West Midlands region. Reports were analysed by all drugs, and most commonly reported drugs ('top drugs'). PCT data, adjusted for population size, were aggregated. Prescribing statistics and other characteristics were obtained for each PCT, and associations between these characteristics and ADR reporting rates were examined. During 2004-06, 1175 reports were received from PCTs. Two hundred and eighty (24%) of these reports were for 14 'top drugs'. The mean rate of reporting for PCTs was 213 reports per million population. A total of 153 million items were prescribed during 2004-06, of which 33% were 'top drugs'. Reports for all drugs and 'top drugs' were inversely correlated with the number of prescriptions issued per thousand population (r(s)=-0.413, 95% CI -0.673, -0.062, P < 0.05, and r=-0.420, 95% CI -0.678, -0.071, P < 0.05, respectively). Reporting was significantly negatively correlated with the percentages of male GPs within a PCT, GPs over 55 years of age, single-handed GPs within a PCT, the average list size of a GP within a PCT, the overall deprivation scores and average QOF total points. ADR reports did not correlate significantly with the proportion of the population over 65 years old. Some PCT characteristics appear to be associated with low levels of ADR reporting. The association of low prescribing areas with high ADR reporting rates replicates previous findings.


  • Laboratory monitoring and adverse patient outcomes with antihypertensive therapy in primary care

    by Sarah E. McDowell, Jamie J. Coleman, Stephen J. W. Evans, Paramjit S. Gill, R. E. Ferner

    Purpose: The monitoring of serum electrolyte and creatinine concentrations in patients treated with antihypertensive therapy is recommended. We wished to examine the relationship between laboratory monitoring and adverse patient outcomes.Methods: We carried out a retrospective cohort study using the General Practice Research Database (GPRD). Patients aged 18 years or older with newly diagnosed hypertension and prescribed a single antihypertensive agent were included. Monitoring was defined as any laboratory test for serum electrolyte and creatinine (or urea) concentrations within 6 months of starting treatment.Results: We identified 74 096 patients who were newly diagnosed with hypertension and prescribed a single antihypertensive agent. Twenty six thousand nine hundred forty six (36.4%) patients had any biochemical laboratory measurement within 6 months. Three hundred ten patients (0.4%) died, 1451 (2%) were admitted to hospital at least once and 29 749 (40.2%) discontinued their first course of antihypertensive treatment within 6 months. Patients were more likely to be admitted to hospital if their biochemistry had been monitored after beginning treatment (adjusted hazard ratio (HR) 1.37; 95%CI 1.21–1.55). They were also marginally more likely to discontinue treatment (adjusted HR 1.04; 95%CI 1.02–1.07). They were not significantly more likely to die (adjusted HR 1.21; 95%CI 0.87–1.67).Conclusions: Biochemical testing at baseline and monitoring after starting treatment is often omitted in newly diagnosed hypertensive patients. Those patients who are monitored are more likely to be admitted to hospital and to discontinue initial antihypertensive therapy, but not to die. Many biochemical adverse drug reactions are found only by laboratory monitoring. Copyright © 2010 John Wiley & Sons, Ltd.